Evidence map›Paper›PMID 27147252›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Safety and efficacy of primary thromboprophylaxis in cancer patients.

I García Escobar, M Antonio Rebollo, S García Adrián, A Rodríguez-Garzotto, A Muñoz Martín, Cancer&Thrombosis Working Group of the Spanish Society of Medical Oncology (SEOM)

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 16 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

I García EscobarServicio de Oncología Médica, Hospital San Pedro de Alcántara, Avda. Pablo Naranjo, s/n., 10003, Cáceres, Spain. naxto@hotmail.com.
M Antonio RebolloICO-Hospital Duran i Reynalds, L'Hospitalet de Llobregat, Barcelona, Spain.
S García AdriánHospital Universitario de Móstoles, Móstoles, Madrid, Spain.
A Rodríguez-GarzottoHospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.
A Muñoz MartínHospital General Universitario Gregorio Marañón, Madrid, Spain.
Cancer&Thrombosis Working Group of the Spanish Society of Medical Oncology (SEOM)
Duran i Reynals Hospital · ESHospital General Universitario Gregorio Marañón · ESHospital San Pedro de Alcántara · ESHospital Universitario de Móstoles · ESHospital Universitario Príncipe de Asturias · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is often complicated by venous thromboembolism (VTE), a common and potentially fatal complication associated with poor prognosis in these patients. An increased incidence of VTE is being observed due to the advanced age of cancer patients, the thrombogenic effect of novel drugs and advances in the diagnosis of related complications. In this review, we look at five different risk groups of cancer patients with an increased probability of developing VTE, including hospitalized patients undergoing chemotherapy, patients undergoing a surgical procedure, ambulatory patients undergoing chemotherapy, patients with a central venous access and patients receiving antiangiogenic drugs or anticoagulant therapy due to previous chronic diseases. The aim of this review is to summarize the most important clinical evidence reported to date on the suitability of primary thromboprophylaxis to cancer patients. Recommendations have drawn up for each group based on current evidence and guidelines to facilitate decision-making in clinical practice.

Indexed as

AnticoagulantsHumansNeoplasmsPrognosisVenous ThromboembolismAnticoagulantsAntiangiogenic drugsCentral venous catheterOncological patientsPrimary prophylaxisThrombosisVenous thromboembolism

Identifiers

PMID27147252
OpenAlexW2345736309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.